Aterosclerosis, Angina, Acute myocardial infarction, Coronary artery disease.
Conditions
Interventions
Patients who meet the study inclusion criteria will undergo a 1-week run-in period using optimized dose-blocking agents associated with a dihydropyridine calcium channel antagonist. At the end of this
Drug
D03.383.606.920
D03.633.100.759.160
Sponsors
Faculdade de Medicina da Universidade Federal da Bahia
Faculdade de Medicina da Universidade Federal da Bahia
Hospital Ana Nery
Eligibility
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patients with stable coronary artery disease (CAD) diagnosis through cardiac catheterization evidencing at least an epicardial coronary artery with stenosis greater than 70%. Symptomatic angina despite clinical treatment optimized with a beta-blocker agent at a maximum tolerated dose and a dihydropyridine calcium channel antagonist agent. Age> 18 years. Consent to participate in the study.
Exclusion criteria
Exclusion criteria: Patients with obstruction of the left coronary artery greater than 50%. Patients who are asymptomatic from angina after initial clinical optimization. Acute myocardial infarction in the last 2 months. Renal insufficiency with creatinine clearance <45ml / min. Hepatic insufficiency. Concomitant use of azathioprine. Refusal to participate in the study and / or sign the informed consent form. Participation in another research protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The intensity of angina after 30 days, assessed by the Seattle angina questionnaire (QAS) score in the angina (QAS-angina) domains measured before the start of the intervention and 30 days after the start of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intensity of angina; evaluated by the total score obtained in all areas of the QAS obtained before the beginning of the intervention and after 30 days;Frequency of angina episodes; evaluated by the number of weekly episodes of angina before the beginning of the intervention and after 30 days;Frequency of episodes of angina during sleep; evaluated by the number of weekly episodes of angina during sleep before the beginning of the intervention and after 30 days;Frequency of use of sublingual nitroglycerin for angina control; evaluated by the amount of weekly tablets of short-acting sublingual nitroglycerin before the beginning of the intervention and after 30 days;Prevalence of significant angina after 30 days; evaluated by the percentage of patients with grade III or IV graded angina after 30 days by the Canadian Cardiovascular Society (CCS) score; positive if the patient has angina triggered by minimal exertion or at rest evaluated before the beginning of the intervention and after 30 days | — |
Countries
Brazil
Contacts
Public ContactRodrigo;Taina Vieira de Melo;Viana
Hospital Ana Nery;Hospital Ana Nery
Outcome results
None listed